EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience

Tingting Chen, Lifei Liang, Siyue Chen, Qing Xu, Xiaoyu Li, Ming Xu, Ruiming Rong, Tongyu Zhu, Cheng Yang

Organ Medicine · 2025

DOI: 10.1002/orm2.70002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Organ Medicine, 2025. Verfasst von Tingting Chen und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The study aims to evaluate the preliminary efficacy and safety of basiliximab in treating acute T cell‐mediated rejection (TCMR) after kidney transplantation, particularly in patients with poor responses to standard treatments.

Methods

We conducted a retrospective case series study involving eight kidney transplant recipients at Zhongshan Hospital, Fudan University, who received basiliximab for anti‐TCMR treatment. Baseline characteristics, immunosuppression management data, and treatment outcomes were collected.

Results

Among the eight patients, two had biopsy‐proven TCMR. Elevated serum soluble IL‐2R (sIL‐2R) level were detected in all patients before basiliximab treatment. Following basiliximab therapy, all patients exhibited a rapid decrease in sIL‐2R levels, and most cases showed a general downward trend in serum creatinine levels. Although two patients developed pulmonary infections posttreatment, no clear correlation was found between the use of basiliximab and infections. No other new infections or adverse reactions were reported.

Conclusions

Basiliximab therapy demonstrates efficacy and good tolerance in patients with TCMR.

Zitieren

APA

Chen, T., Liang, L., Chen, S., Xu, Q., Li, X., Xu, M., Rong, R., Zhu, T., & Yang, C. (2025). Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience. Organ Medicine. https://doi.org/10.1002/orm2.70002

Vancouver

Chen T, Liang L, Chen S, Xu Q, Li X, Xu M, et al. Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience. Organ Medicine. 2025. doi:10.1002/orm2.70002

BibTeX
@article{Chen2025,
  author = {Chen, Tingting and Liang, Lifei and Chen, Siyue and Xu, Qing and Li, Xiaoyu and Xu, Ming and Rong, Ruiming and Zhu, Tongyu and Yang, Cheng},
  title = {Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience},
  journal = {Organ Medicine},
  year = {2025},
  doi = {10.1002/orm2.70002}
}
Kostenlos starten →